However, long-term administration of IGF1, even if effective, might not be an appropriate treatment for sarcopenia and cachexia because insulin-IGF1 signaling has been shown to promote cancer growth and to shorten lifespan (Kenyon, 2010). Here, INS is linked to sarcopenia.